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As Illich pointed out many years ago, a drug's commercial and medical success is not terribly dependent on its chemical effects on the body (Illich 1976, 72) . This observation has given impetus to critical work on pharmaceuticals that explores factors which make drugs as varied as Viagra, antidepressants and Botox so successful (Fishman and Mamo 2001; Elliot 2003; Moynihan and Cassels 2005; Marshall 2006; Petryna and Kleinman 2006) , and spawned studies of the way pharmaceuticalization influences medical and social practices (Williams et al. 2011a) . In this body of work it becomes clear that one important factor, among many, that can impact a drug's success is the way it is constructed and situated in the professional medical discourse and the medical infrastructure of a specific country, a trait pharmaceuticals share with many other medical technologies (see Healy 2000; Löwy 2015) . This section of this book explores local examples of a pharmaceutical's ability to influence the treatment of established medical conditions and redefine health problems as issues with a pharmaceutical solution. The previous chapter explored the influence Viagra had on the medical discourse in Sweden. In this chapter, I am again relying on an analysis of the medical discourse in the Swedish-language medical journal Läkartidningen. From it, I have retrieved research articles and debate pages that appear when the journal's online archive is searched for the Swedish words associated with lower urinary tract symptoms secondary to benign prostate hyperplasia (LUTS/BPH): BPH, prostatahyperplasi and prostatahypertrofi.
1 I have conducted a search for the years between 1990 and 2015, since alpha-blockers started to become a more common treatment method in Europe for LUTS/BPH in the 1990s (EUA 2006, 35) and were registered as a treatment for BPH in Sweden in the early 1990s (Carlsson and Spångberg 1996a, 4549; Hallin 1999, 3520) . This time frame mirrors that used for Viagra in the previous chapter.
Alpha-blockers are an interesting case for a book about glocal pharmaceuticalization because they show an example of incomplete change in the medical discourse and clinical practice for the treatment of LUTS/BPH, as opposed to Viagra, which completely changed the face of a disease and its treatment. Alphablockers are also related to an analysis of Viagra because one of their side effects is impotence and/or erectile dysfunction. Medical guidelines suggest that men taking alpha-blockers may experience decreased desire and erectile and ejaculatory difficulties (EAU 2006; AUA 2010; SBU 2011) . Many men who receive a prescription for alpha-blockers will also receive a prescription for Viagra, although probably to very limited success, given that Viagra does not address desire.
Alpha-blockers are being prescribed to treat LUTS/BPH in Sweden as in other developed, Western countries. In fact, some Swedish experts assert that they are being overprescribed. Yet, despite their presence in the Swedish cadre of treatments for close to twenty-five years, and despite their place as an early course of action for LUTS/BPH, according to an official Swedish diagnostic and treatment report (SBU 2011), they have not managed to replace surgical treatments as completely as Viagra managed to replace sex therapists in the Läkartidningen discourse or out in the urology clinics. By the early 2000s, 40,000 men were being treated pharmaceutically for BPH in Sweden (Dahlstrand 2003 (Dahlstrand , 2678 , and by 2009, this number had risen to approximately 115,000 (Spångberg and Dahlgren 2013, 685), a significant increase, even if one considers the possibility that pharmaceutical treatments also increased the gross number of patients diagnosed with LUTS/BPH. At the same time, surgical procedures had declined, but were still relatively high. In 1987, before alpha-blockers, 12,000 surgeries for enlarged prostates were performed in Sweden. In 2009, just under 5,000 were performed (Spångberg and Dahlgren 2013, 685) . This is a decrease, but shows that surgery is still the treatment option for thousands of Swedish men each year and is still presented as an option in the discourse in Läkartidningen.
LUTS/BPH and alpha-blockers
The search terms I used for this study are the Swedish words which are or have recently been applied to what is today known as LUTS/BPH, lower urinary tract symptoms secondary to benign prostate hyperplasia in English. This is a condition in which the prostate becomes enlarged but without being cancerous. The prostate can start to grow again in older men, gradually increasing in size with age, and this is thought to happen in the majority of men. For some, it happens around age fifty, for others, not until they are seventy or older. It is a normal development, but this normal growth can cause problems with urination and is thus considered pathological. By the age of seventy, 75% of men will have LUTS/BPH symptoms, that is problems urinating (Parsons 2007, 395) , and by age eighty, nearly all men will have an enlarged prostate (Fall 1999 (Fall , 2227 , 80% of whom will have problems with urination (Dahlstrand 2003 (Dahlstrand , 2678 . These statistics tend to vary a bit, but the general understanding is that the prostate gets larger as men get older, and that causes problems urinating.
Urologists like to point out that urination issues for men have existed for thousands of years, referring to drawings on Egyptian papyrus from the fifteenth century BC and to writings by Hippocrates (Shackley 1999, 776) . Medically, however, the prostate as a separate organ was not represented in European anatomy diagrams until 1536, and not named until 1611 (Marx and Karenberg 2009, 209) . Successful methods of surgically addressing the prostate for urination difficulties did not really evolve until just more than 100 years ago (Shackley 1999, 776) . Today, a connection is often made between male urinary problems and an enlarged prostate. It is thought that when the prostate gets larger it may also start to block the urethra, the tube that lets the urine pass from the bladder and which the prostate surrounds, like a straw stuck through a ball. When the prostate begins to block the flow of urine through the urethra, its enlargement becomes a problem.
The first step of treatment for LUTS/BPH is currently pharmaceutical. This is a relatively recent change and it has complemented but not entirely replaced the traditionally more common surgery. Around the turn of the twentieth century, surgeries were performed for prostate issues, but with very high risks primarily due to infection. These surgeries would access the prostate from the abdomen or, more commonly, through a Y-shaped incision behind the testicles. These days, the LUTS/BPH prostate is usually surgically accessed through the urethra and the most common method is by transurethral resection of the prostate (TURP), which sends a tool in through the urethra to scrape away and cauterize the prostate tissue from the inside (AUA 2010, 70) . There are other mechanical ways of removing or destroying a prostate diagnosed with LUTS/BPH, including microwave thermotherapy, radiofrequency needle ablation and laser therapies, but besides pharmaceuticals, surgery is the most common method in Sweden (SBU 2011).
Pharmaceutical treatment can be traced to the introduction of alpha-blockers in the 1970s (Heyns and de Klerk 1989, 226) and their eventual position as a standard treatment starting in the 1990s. However, even before alpha-blockers, LUTS/ BPH had been treated by suppositories, herbal treatment, chemicals and hormones. Chemical preparations doctors historically prescribed for patients include opium, silver nitrate and belladonna suppositories, potassium iodine, potassium bromide, ergot (a type of fungi that grows on rye) and large quantities of distilled water (Marting 1903, 52; O'Shea 2012, 14) . Many of these treatments were directed at the symptoms the man presented with, primarily urination problems, and some of the elixirs irrigated the bladder, but others, like ergot, were actually thought to shrink the prostate gland (O'Shea 2012, 14) .
At the end of the nineteenth century, it was generally thought that 'orchidectomy' (surgically removing one or both of the testicles) and vasectomy could be two treatments for the enlarged prostate that may have beneficial effects (Heyns and de Klerk 1989, 204; Shackley 1999, 777) . This theory was in part developed because the then-current surgical methods (primarily suprapubic prostatectomy) had a mortality rate of about 20%, so other treatment methods were very welcome by patients and doctors alike. But the ideas about using castration and vasectomy could also be traced to the observation that eunuchs and those with non-developed testicles never presented with 'hypertrophy' of the prostate (Ciechanowski 1903, 91) , indicating that the testes were somehow involved in the development of prostate growth later in life. While clinical practice did not really support the use of castration for treatment -many doctors reported that it was not successful and that patients were not pleased with the results (Marting 1903) -the possibility that it could work eventually led to theories about the role of hormones in prostate enlargement. However, it took until sometime into the twentieth century before hormone therapies were widely developed and used for prostate issues (O'Shea 2012, 17; see also Oudshoorn 1994 , 2003 and Sengoopta 2006 for general histories of hormone treatments and their relationship to masculinity). In the 1930s and 1940s, androgens, especially testosterone, were used to treat patients with what was then called 'prostatism', but without much success. The next step was to try oestrogen and combinations of oestrogen and testosterone. This did not really work to reduce the prostate, either, although it did seem to give some relief of symptoms and increase urine flow (Heyns and de Klerk 1989, 221) . In the 1970s and 1980s a series of trials were done on antiandrogens and progestins. Some of these showed symptom improvement and others did not, and many of the trials had quite a few side effects, like vertigo, shivering, tiredness, loss of libido and impotence (Heyns and de Klerk 1989, 221-3) . Cholesterol-lowering drugs were also tested, but with no significant benefit (Heyns and de Klerk 1989, 23-4) .
At the same time, in the 1970s and 1980s, doctors also began to try alphablockers, with more success. They seemed better than placebos at treating peak and average flow rates of urination, the amounts of residual urine and even the prostatic urethral pressure (Heyns and de Klerk 1989, 226) , so much so that it has been suggested that their relative success may also have increased the interest in diagnosing LUTS/BPH (Ekman 1999, 3504) . It is this category of drugs, alphablockers, that I will explore in the Swedish medical literature.
Alpha-blockers
Alpha-blockers' main purpose as a treatment for LUTS/BPH is to reduce the symptoms and bother of urination problems (SBU 2011, 317) , and their use has steadily increased since the 1990s, probably in part because patients (and their doctors) see them as a way of avoiding surgery and in part because of increased marketing from pharmaceutical companies (EUA 2006, 35) .
Alpha-blockers work on the smooth muscle tissue of the prostate. One theory about the cause of LUTS/BPH is that, as the prostate increases in size, the increase in prostatic smooth muscle tissue interferes with urethral constriction and impairs the flow of urine (AUA 2010, 13) . Reducing this process and changing the behaviour of the smooth muscle cells by ingesting alpha-blockers can then help to relieve the blockage and enable better urination. However, alpha-blockers, which are ingested orally, do not only work on the muscle cells of the prostate; they can affect smooth muscle cells all over the body, which leads to side effects like headaches, dizziness, hypertension, retrograde ejaculation and, as mentioned earlier, sometimes erectile dysfunction. Newer versions of alpha-blockers, which are better at targeting the prostate specifically, are being developed and marketed, but for the most part, treatment with alpha-blockers is followed by various side effects.
If alpha-blockers are going to work for a man, he should notice a difference relatively quickly, some within forty-eight hours, and no longer than a month after beginning treatment (EUA 2006, 36) . Different ways of measuring the results of treatment are commonly used to determine if alpha-blockers are effective, including reiterations of the symptom scale questionnaire, pressure, flow and volume measures and by measuring the volume of the prostate, to see if it has shrunk at all. A third of men will not notice any symptom improvement at all (EUA 2006, 36) and, according to Swedish pharmaceutical registry statistics, two-thirds of the men will stop taking alpha-blockers within three years (Spångberg and Dahlgren 2013, 685) . If they do work, the patient can continue taking the alpha-blockers for the rest of his life.
Thus, the actual success of treating LUTS/BPH with alpha-blockers is contested. The American Urology Association (AUA) says that alpha-blockers 'produce significant symptom improvement compared to placebo that the average patient will appreciate as a moderate improvement from baseline' (AUA 2010, 28) . But what is significant is a matter of debate. In the national Swedish report for treatment of LUTS/BPH done by the Swedish Agency for Health Technology Assessment, alpha-blockers are said to reduce the symptom bother slightly and increase the flow rate slightly better than placebos (SBU 2011, 321) . The results are statistically significant but rather small (SBU 2011, 335) . As the European Association of Urology (EAU) guidelines suggest, there are very real placebo effects to take into consideration (EAU 2006, 35) and, as the SBU overview noted, there is always a publication bias to statistical evaluations based on published studies; unsuccessful studies do not tend to be published. Of all the published studies that the SBU found to evaluate, none had been financed by independent sources; all were funded by the pharmaceutical industry (SBU 2011, 317-18) . They suggest that it is important to remember that scientific and commercial interests have influenced the design, conduct and evaluation of the studies on which conclusions about alpha-blockers are based (SBU 2011, 325) . My analysis of the medical discourse in Läkartidningen would suggest that resource distribution and professional hierarchies implicit in the structural organization of professional health care in Sweden are also relevant factors in the moderate success of alphablockers within the process of pharmaceuticalization of LUTS/BPH. They are not the only factors, but they are involved.
Alpha-blockers for LUTS/BPH in Läkartidningen
Treatment for LUTS/BPH in Sweden can take one of three paths -and sometimes all three through the course of the disease. One can engage in 'watchful waiting', which means the patient is sent home and told to keep an eye on things and come back if his urination problems become more serious. If the patient is already so bothered by his LUTS/BPH that watchful waiting is not an option, the treatment can either be lifelong medication, beginning with the use of alpha-blockers, potentially combined with 5-Alpha-reductase inhibitors (5-ARIs), or the problem can be addressed surgically or through other means of removing or destroying the prostate. (There are natural dietary supplements, herbal medicines and exercise programmes which are also said to help, but these are not covered by the urologydominated discourse in Läkartidningen.)
Alpha-blockers could have been a game changer for the treatment of LUTS/ BPH when they were introduced in the 1990s. And to some extent, they have been, but not entirely. When they started being used, the main treatment for severe BPH was surgery. The surgical removal of parts of the prostate through the urethra has been in general use in Sweden since the end of the 1960s (Hedelin et al. 2003 (Hedelin et al. , 2441 . However, the introduction of alpha-blockers has not removed surgery as an option for treatment, even if the official diagnostic and treatment overview (SBU 2011) suggests that alpha-blockers are a first-step treatment, to be tried before surgical removal or reduction of the prostate. Yet surgery for an enlarged prostate and the urination problems it is thought to cause is still a very widely used method in Sweden (and in other countries), and the surgical techniques are continually being advanced technically, with hospitals purchasing expensive robotic surgery systems, partly as recruitment tools to attract urology surgeons (Lindgren 1999), and TURP simulators for training purposes are being developed and used (Käll-ström 2010). The most recent articles in Läkartidningen mention both surgery and pharmaceutical treatments on equal grounds (Degerblad et al. 2014) . So, as an example of pharmaceuticals changing the treatment practices of already medicalized diseases, alpha-blockers are only partially successful.
When they arrived on the scene, alpha-blockers did not have to do any convincing about the 'realness' of LUTS/BPH or its presence in the enlarged prostate diagnosis. Problems with urination had already been accepted, both the legitimacy of patient suffering and the legitimacy of paying for treatment with tax money in Sweden. LUTS/BPH was an established disease with established treatments that were costly and that cost was not controversial. What was controversial in the Swedish medical discourse was shifting that cost from surgery provision to pharmaceutical distribution. In 1996, an article about new, expensive pharmaceuticals for urological treatments, written by a leading urologist, compared their increasing costs (and potential share of a limited health care budget) with the cost of more traditional urology care, claiming that the increased costs for medicines for prostate cancer, BPH and erectile dysfunction 'would equal the annual costs of running between five and six medium sized urology clinics' 2 (Carlsson and Spångberg 1996a, 4552) . In this argument the cost of medication is directly compared to the cost of funding clinical treatments in urology. Resources for drugs are rhetorically placed in direct competition with urologists' salaries and clinical costs.
The concern about cost is particularly relevant to the local context of alphablockers in Sweden, reflecting both the tax-based structure of health care funding in Sweden and the fact that LUTS/BPH treatments are accessed within a health care system that has designated specialists -urologists -who treat LUTS/BPH and gatekeepers to those specialists, general practitioners. With alpha-blockers, there was debate and concern about cost in general, although the concern seems to be more related to the fact that use of alpha-blockers for the treatment of LUTS/ BPH is a lifelong medication, whereas the (arguably expensive) surgery it is sometimes thought to replace is a one-off cost (Hedelin et al. 2001 (Hedelin et al. , 2441 . However, in the debate about whether to treat with alpha-blockers or to treat with surgery also lurked an implication of which type of doctor was allowed to treat LUTS/ BPH and where the state resources for it would then go. In Sweden, a man with suspected LUTS/BPH cannot make an appointment with an urologist on his own; he must receive a referral to the urology specialist from his general practitioner. General practitioners are not allowed to conduct TURP surgeries, but they canat least theoretically -prescribe alpha-blockers (Hassler 2002 (Hassler , 2174 . By shifting the first line of treatment to alpha-blockers, there is the potential that LUTS/BPH patients will become a case for general practitioners but not urologists. To some extent this has happened, but not entirely, and here, too the medical discourse has focused on how alpha-blockers can potentially shift cost and resource distribution within the health care system (Carlsson and Spångberg 1996b, 4557) . In the early 2000s, it was estimated that one in four patients was beginning treatment with alpha-blockers or other pharmaceuticals before visiting a urologist (Hedelin et al. 2003 (Hedelin et al. , 1435 ). This does not mean that urologists have lost 25% of their LUTS/ BPH patients -on the contrary. There has been a dramatic rise in the number of patients presenting with LUTS/BPH since the early 1990s, probably due to the existence of alpha-blockers and their use as a treatment at an earlier stage in the disease. But nonetheless, the discourse in Läkartidningen shows a concern about patients being treated outside of, and prior to, consultation with a urology specialist, despite that the Swedish urology field is currently understaffed and there are long waiting lists for meeting a urologist, as the field is very occupied with prostate cancer.
For the treatment of LUTS/BPH, a shift from being a disease treated by specialists to one managed by general practitioners can also carry with it a step down the prestige ladder (see Witz 1992; Lindgren 1999), and one which could mean a transfer of resources from the more prestigious speciality (urology) to the less prestigious world of general practitioners, as the comparison of increasing costs of pharmaceutical treatments to clinic costs could suggest. This competition between GPs and urologists has been articulated elsewhere, like in the debate about whose finger is better at conducting the digital rectal exam of the prostate, the general practitioner's or the urologist's (see Kirby et al. 1995) . It may have had an influence on the extent to which alpha-blockers replaced surgery in the Swedish context.
The final words in the debate between alpha-blockers and surgical treatments for LUTS/BPH may yet remain to be written. One of the urologists I interviewed suggested that the new framing of BPH as primarily LUTS in the 2013 European Association of Urology clinical guidelines (Oelke et al. 2013 ) is a result of alphablockers -or lobbying by their producers and supporters -to change the focus from the enlarged prostate to the lower urinary tract symptoms and thereby shift the focus from potentially removing an enlarged gland and instead treating the muscles in and around it with pharmaceuticals.
More recently, there has been little debate about the use of alpha-blockers in Läkartidningen, which would suggest that the usage has stabilized. Alpha-blockers' place in treatment practice has also been formalized in the 2011 overview published by the Swedish Agency for Health Technology Assessment. The chair of the committee who authored this report is the same urologist who raised the comparison of costs in relation to urology clinics in 1996, and who wrote a 2013 article in Läkartidningen reviewing the overview. His voice, together with the health care policy analysts he co-authored with, raised concerns about the (over) use of alpha-blockers, while simultaneously noting their relatively small success rate (Spångberg and Dahlgren 2013, 683) .
Strong and weak pharmaceuticalization: alpha-blockers and Viagra in Läkartidningen
As discussed in Chapter 4, Viagra changed the concept of ED and impotence, its treatment and even who its patient was in the Swedish medical discourse, as it did in the international discourse. Yet particularly local Swedish aspects appeared in the discourse around Viagra, related to local (nation state) health care provision specificities, particularly the division of labour between GPs and specialists, and the funding structures for clinical care and pharmaceutical provision. There are some similarities here to what happened with alpha-blockers in the Läkartidnin-gen discourse, but also some significant differences.
One similarity between the Viagra discourse and that surrounding the use of alpha-blockers is the concern about cost, yet there are some significant differences between them, too. This was a very heated debate about Viagra, and dealt primarily with the potential costs a state subsidy of the pharmaceutical would entail, an argument that spilled over into the court system, as Chapter 2 detailed. The Viagra cost debate focused on the sheer (potential) cost of the drug for a desiring public and its legitimacy within a tax-funded system, based on the question of whether old-age impotence was a legitimate disease to spend tax resources on. Within the alpha-blocker debate, the question of cost was framed as one of where within the health care system the disease would be treated, and whether resources should be used to support clinics or pharmaceuticals. The legitimacy of spending tax money to treat LUTS/BPH was never questioned.
Viagra also changed the way impotence (now ED) was treated, which alphablockers only partially managed to do. Here the most interesting difference with alpha-blockers can be found. Perhaps the incompleteness of the shift from surgery to pharmaceutical treatment is because the representatives of the other method of treatment (surgery) are not from a less prestigious and weaker field of medicine. In the Viagra case, when Viagra was introduced it shifted the event of impotence from a problem for sexual and couples therapists to a disease (ED) under the remit of urologists. The urologists were able to claim this territory from the sex therapists without much visible resistance. However, LUTS/BPH was already a disease of urology when the pharmaceuticals arrived on the scene and despite indications that general practitioners may be beginning to prescribe alpha-blockers for it, urologists are trying to keep LUTS/BPH in their remit. Rather than facilitating a shift from one medical field to another, alpha-blockers merely created two different factions within urology: those who were still using surgery, and those who were willing to treat LUTS/BPH with pharmaceuticals.
Given that the introduction of alpha-blockers could have replaced an expensive, invasive surgical procedure, one could have expected it to cause a change in treatment practices more readily and thoroughly, as Viagra did. But this was not the case. Surgical procedures are down significantly from their occurrence rate before alpha-blockers were officially part of the treatment cadre, but there are still many thousands conducted each year in Sweden. Perhaps one clue to why can be found in the fact that with Viagra there was no actor who/which had traditionally received large resources for the treatment of impotence. Sexual therapists existed (and still exist) in Sweden, but their branch of medicine was peripheral compared to urology, and not nearly as well funded. The occurrence of impotence was medicalized, but its treatment costs were minimal and it was somewhat considered a natural part of getting older that men should just accept (see McLaren 2007) . This was not the case with urination problems. The shift of ownership of impotence from sex therapists to urologists that Viagra facilitated was from a low-prestige field to a higher-prestige one. But for alpha-blockers, the potential shift was from a surgical branch of urology to a non-surgical branch of urology. This can either be considered two equal branches in the same field, or envisioned as a shift from a high-prestige to a lower-prestige branch in the same field of medicine, depending on how one sees it (cf. Lindgren 1999). Alpha-blockers were not a tool that could be used to capture the right to diagnose and treat a problem from one specialty to another. Urologists were already conducting surgeries for LUTS/BPH, and it is primarily urologists who are prescribing alpha-blockers. Increasing their use could potentially allow GPs more space in the game, but the urologists seem to be a more powerful voice in the discourse. In fact, no GPs were authoring articles about LUTS/BPH and alpha-blockers in Läkartidningen during the period studied, unlike the Viagra discourse, which saw a shift in who was the author of most of these texts. In the alpha-blockers for LUTS/BPH discourse, nearly all of the articles are written by or giving the opinions of urologists -eleven of themthroughout the entire time period searched, with the exception of a few pharmacists and pharmaceutical policy analysts. This is different than the authors, who were given space in the Viagra discussion, where sex therapists and sexologists were writing about impotence before Viagra, and urologists were writing about erectile dysfunction after Viagra's arrival.
The case of alpha-blockers in Sweden can nuance our understanding of pharmaceuticalization by showing that the existence of the drug and its acceptance into the official retinue of treatment options is not enough to predict the success of a new pharmaceutical treatment. Success is also related to which actors (individuals, commercial interests and medical practitioners, a heterogeneous category) use the drugs to make the shifts that occur. Locally, with the case of alpha-blockers in Sweden, the specific concerns with cost and resource distribution related to the government-financed organization of speciality clinics may have impacted the amount of success the alpha-blocker treatment has had in replacing existing therapies, and seems to certainly have influenced the way it was presented in the medical discourse.
Alpha-blockers have become an earlier step in the disease trajectory, a sort of middle stage before eventual treatment with surgery, even though many men are prescribed alpha-blockers with the idea that they will have to take them for the rest of their lives, and may avoid surgery by doing so. The ability of alpha-blockers to shift the treatment paradigm of an existing medical condition from surgery to pharmaceutical has been weaker than that of Viagra. But they have still managed to take over some of the patients and, perhaps more important, they have managed to increase the number of patients identified as having LUTS/BPH. Alpha-blockers have been part of a process of pharmaceuticalization of an existing medical condition, but this process has been only partially successful.
Notes
1 There has been a more recent debate about the dangers of using an anti-inflammatory drug for BPH because of its negative effect on heart patients already taking glucosamine, a debate that has primarily been related to Pfizer's heavy marketing of Artrox, its alleged influence on Swedish safety and side-effect recommendations to doctors, Pfizer's alleged attempts to debunk studies which criticize its effectiveness and safety, and its increased cost, compared to other drugs (see Beermann 2003; Fuberg 2003a Fuberg , 2003b Järhult and Lindahl 2003a , 2003b , 2003c Lohm and Lindh 2003; ; Nilsson et al. 2003; Lohm et al. 2003; Järhult 2005) . This is not an alpha-blocker and is therefore not analyzed in this chapter. 2 All translations are the author's.
